- Home
- KGEI vs ALEC Comparison
KGEI vs ALEC Comparison
Compare KGEI & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KGEI | ALEC |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | 103 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.0M | 228.7M |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KGEI | ALEC |
|---|---|---|
| Price | $4.67 | $2.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 230.2K | ★ 821.6K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $32.37 | $2.03 |
| Revenue Next Year | $4.72 | $29.87 |
| P/E Ratio | $7.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.35 | $1.09 |
| 52 Week High | $6.61 | $3.40 |
Technical Indicators
Market Signals| Indicator | KGEI | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 59.47 |
| Support Level | $4.50 | $1.93 |
| Resistance Level | $5.92 | $2.64 |
| Average True Range (ATR) | 0.28 | 0.16 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 16.19 | 88.44 |
Price Performance
Historical ComparisonAbout KGEI Kolibri Global Energy Inc.
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.